World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
44109
World Ranking
7296
National Ranking
3820

John Nemunaitis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John Nemunaitis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 628 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John Nemunaitis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John Nemunaitis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John Nemunaitis is affiliated with Gradalis in the United States and has contributed extensively to medical research, primarily focusing on oncology and related biomedical fields. Their work spans from clinical trials to biomarker and immunotherapy research, with a broad interdisciplinary approach crossing medicine, biochemistry, genetics, and molecular biology.

The scientist has published in prominent venues, with frequent publications in the following journals:

  • Journal of Clinical Oncology
  • Future Oncology
  • Gynecologic Oncology
  • Cancer Gene Therapy
  • Oncology Reviews

Nemunaitis' primary fields of study include Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on subfields such as Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Genetics.

The main topics in Nemunaitis' research portfolio cover a diverse set of areas related to cancer and immune therapies:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Research and Treatments
  • PARP inhibition in cancer therapy
  • Ovarian cancer diagnosis and treatment
  • Cancer Genomics and Diagnostics

Notable recent papers by Nemunaitis include:

  • "Ovarian Cancer Immunotherapy and Personalized Medicine" (2021), published in International Journal of Molecular Sciences
  • "TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials" (2020), in Cancer Gene Therapy
  • "First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors" (2020), published in Journal of Clinical Oncology
  • "Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer" (2023), in Journal of Clinical Oncology
  • "The Abscopal Effect of Radiation Therapy" (2021), published in Future Oncology

Frequent collaborators in Nemunaitis' research include Laura Stanbery, Ernest Bognar, Rodney P. Rocconi, Adam Walter, and Luisa Manning, reflecting collaborative efforts across clinical and scientific disciplines. The partnership with these colleagues has resulted in numerous co-authored studies enhancing the understanding of oncology and immunotherapy.

Best Publications

  • Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

    David H. Johnson;Louis Fehrenbacher;William F. Novotny;Roy S. Herbst

  • Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

    Eric J. Small;Paul F. Schellhammer;Celestia S. Higano;Charles H. Redfern

  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    R H Collins;O Shpilberg;W R Drobyski;D L Porter

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

    Alan B. Sandler;J. Nemunaitis;C. Denham;J. Von Pawel

  • Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer

    Celestia S. Higano;Paul F. Schellhammer;Eric J. Small;Patrick A. Burch

  • siRNA vs. shRNA: similarities and differences.

    Donald D. Rao;John S. Vorhies;Neil Senzer;John Nemunaitis

  • Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

    Neil N. Senzer;Howard L. Kaufman;Thomas Amatruda;Mike Nemunaitis

  • Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer

    Stephen G. Swisher;Jack A. Roth;John Nemunaitis;David D. Lawrence

  • Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

    J. Nemunaitis;F. Khuri;I. Ganly;J. Arseneau

  • Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

    John Nemunaitis;John Nemunaitis;John Nemunaitis;Susan N. Rabinowe;Jack W. Singer;Jack W. Singer;Jack W. Singer;Philip J. Bierman

  • Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an E1B-55kD Gene-deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial

    John Nemunaitis;Ian Ganly;Fadlo Khuri;James Arseneau

  • Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer

    J. Nemunaitis;S.G. Swisher;T. Timmons;D. Connors

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

    Dan Laheru;Eric Lutz;James Burke;Barbara Biedrzycki

  • Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

    John Nemunaitis;Robert O. Dillman;Paul O. Schwarzenberger;Neil Senzer

  • Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.

    John Nemunaitis;Casey Cunningham;Neil Senzer;Joseph Kuhn

  • Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

    J. Nemunaitis;C. Cunningham;A. Buchanan;A. Blackburn

  • MicroRNA profile analysis of human prostate cancers

    A W Tong;P Fulgham;C Jay;P Chen

Frequent Co-Authors

Neil Senzer
Neil Senzer Gradalis (United States)
Howard L. Kaufman
Howard L. Kaufman Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Jack W. Singer
Jack W. Singer University of Washington
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Sunil Chada
Sunil Chada The University of Texas MD Anderson Cancer Center
Kunle Odunsi
Kunle Odunsi Roswell Park Cancer Institute
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Jack A. Roth
Jack A. Roth The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in the healthcare field but not sure traditional medical school is right for you, there are many alternative pathways to consider. Online degrees in related areas can provide flexible and accessible options that lead to rewarding careers in medicine and health services.

For those drawn to nursing, many direct admit nursing programs make it easier to start your nursing career, offering streamlined admission processes. Additionally, you can find absn programs that don't require teas or other standardized tests, making accelerated nursing degrees more accessible for qualified applicants.

If you prefer working behind the scenes in healthcare, consider exploring Medical Billing and Coding. One important question is can you get financial aid for medical billing and coding? Many accredited online programs do offer financial assistance, helping you get started with less financial burden.

For those interested in healthcare leadership, healthcare administration degrees can open doors to management roles in hospitals, clinics, and other organizations. Whichever path you choose, online study options provide a flexible way to advance your education and career in healthcare.

Best Scientists Citing John Nemunaitis

Trending Scientists

Recently Published Articles